# Symptomatic Therapy for Patients With Huntington's Disease

> **NCT04071639** · PHASE1 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 60 (estimated)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** Haloperidol 2Mg Tab
- **DRUG:** Risperidone 1Mg Tab
- **DRUG:** Zoloft 50Mg Tablet
- **DRUG:** Idebenone
- **DRUG:** Deutetrabenazine Oral Tablet [Austedo]

## Key facts

- **NCT ID:** NCT04071639
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-12
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04071639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04071639, "Symptomatic Therapy for Patients With Huntington's Disease". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT04071639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*